These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2401310)

  • 21. [Effects of KW-3635 on the diuretic action of furosemide in rats].
    Kawakage M; Ishihara N; Karasawa A; Kase H
    Nihon Yakurigaku Zasshi; 1993 Jan; 101(1):33-8. PubMed ID: 8444379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effects of KW-3635, a thromboxane A2 antagonist, on arachidonic acid-induced transient cerebral ischemia in dogs.
    Satoh H; Kobayashi T; Higo K; Karasawa A
    Jpn J Pharmacol; 1994 May; 65(1):45-50. PubMed ID: 8089929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of thromboxane A2/prostaglandin H2 receptors in porcine coronary artery--the inhibitory effect of a novel dibenzoxepin derivative, KW-3635.
    Miki I; Ishii A
    Thromb Haemost; 1992 May; 67(5):582-4. PubMed ID: 1387741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective action of 6-keto-prostaglandin E1 in traumatic shock.
    Araki H; Lefer AM
    Prostaglandins Med; 1979 Apr; 2(4):277-84. PubMed ID: 575862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in activities of thromboxane A2 receptor antagonists in smooth muscle cells.
    Miki I; Kase H; Ishii A
    Eur J Pharmacol; 1992 Oct; 227(2):199-204. PubMed ID: 1426029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effects of a novel thromboxane analog in lethal traumatic shock.
    Lefer AM; Araki H; Smith JB; Nicolaou KC; Magolda RL
    Prostaglandins Med; 1979 Sep; 3(3):139-46. PubMed ID: 552102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.
    Shirakura S; Higo K; Takeda M; Karasawa A
    Jpn J Pharmacol; 1994 Jun; 65(2):93-8. PubMed ID: 7967232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective effect of KW-3635, a specific thromboxane A2-receptor antagonist, on experimental glomerulonephritis in mice.
    Kawakage M; Sato K; Karasawa A
    Jpn J Pharmacol; 1994 Jun; 65(2):163-6. PubMed ID: 7967228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial actions of CP-0127, a novel bradykinin receptor antagonist, in murine traumatic shock.
    Christopher TA; Ma XL; Gauthier TW; Lefer AM
    Am J Physiol; 1994 Mar; 266(3 Pt 2):H867-73. PubMed ID: 8160833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of KW-3635, a specific thromboxane A2-receptor antagonist, on the development of lupus nephritis in NZB x NZW F1 mice.
    Kawakage M; Mizumoto H; Nukui E; Sato S; Karasawa A
    Jpn J Pharmacol; 1993 Dec; 63(4):433-8. PubMed ID: 8121078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effects of the specific thromboxane receptor antagonist (+)-S145Na in splanchnic artery occlusion shock in rats.
    Furlan LE; Johnson G; Siegfried M; Lefer AM
    J Pharmacol Exp Ther; 1990 May; 253(2):525-9. PubMed ID: 2140129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock.
    Bitterman H; Smith BA; Lefer AM
    Arzneimittelforschung; 1988 Oct; 38(10):1389-93. PubMed ID: 3196378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs.
    Higo K; Karasawa A
    Jpn J Pharmacol; 1993 Dec; 63(4):521-3. PubMed ID: 8121085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective effects of a platelet activating factor (PAF) antagonist and its combined treatment with prostaglandin (PG) E1 in traumatic shock.
    Terashita Z; Stahl GL; Lefer AM
    J Cardiovasc Pharmacol; 1988; 12(5):505-11. PubMed ID: 2468048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel thromboxane A2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion.
    Higo K; Sano J; Karasawa A; Kubo K
    Arch Int Pharmacodyn Ther; 1993; 323():32-49. PubMed ID: 8250642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the splanchnic visceral organs in development of tolerance to traumatic shock.
    Araki H; Sollott SJ; Lefer AM
    J Trauma; 1980 Dec; 20(12):1046-51. PubMed ID: 7452749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial actions of prostacyclin in traumatic shock.
    Lefer AM; Sollott SL; Galvin MJ
    Prostaglandins; 1979 May; 17(5):761-7. PubMed ID: 386429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of oligotide, a novel oligodeoxyribonucleotide, in murine traumatic shock.
    Skurk C; Nuss C; Lefer AM
    Shock; 1995 Jan; 3(1):13-20. PubMed ID: 7531603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.